The Changing Landscape of Diabetes Data Sharing

The adoption of Continuous Glucose Monitoring (CGM) systems has fundamentally shifted how diabetes is managed. These devices produce a continuous, high-resolution data stream of interstitial glucose levels, providing patients and clinicians with actionable insights that were unimaginable with traditional fingerstick methods. This data, however, is deeply personal and clinically sensitive. As the ecosystem around CGM technology expands, the data frequently flows beyond the initial patient-device relationship to a wide array of third parties—including cloud service providers, artificial intelligence algorithms, pharmaceutical companies, health insurers, and family caregivers. While this data liberalization can power better algorithms, streamline population health management, and deepen patient engagement, it also introduces a complex array of legal and ethical risks. Realizing the full potential of CGM data requires stakeholders to build a governance framework that balances innovation with stringent protections for privacy, autonomy, and equity. This article provides a comprehensive examination of the current legal mandates, ethical imperatives, and practical strategies for responsibly sharing CGM data with third parties.

The Core Ecosystem: Mapping CGM Data Flows and Stakeholders

Understanding the legal and ethical dimensions begins with a clear map of how CGM data moves and who touches it. A typical modern CGM system involves several distinct layers:

  • The Sensor and Transmitter: The hardware worn by the patient that measures interstitial glucose and broadcasts it wirelessly.
  • The Local Application (Smartphone App or Reader): Receives biometric data from the transmitter, displays current glucose values, stores historical data locally, and forwards data to the cloud.
  • The Manufacturer’s Cloud Platform: Centralized backend infrastructure that aggregates data from millions of devices, runs analytical algorithms, and provides patient-facing portals and clinician-facing dashboards.
  • The Third-Party Application or Service: Any entity that receives data from the manufacturer’s platform via an API, SDK, or direct data sharing by the user. This includes digital health coaching apps, research study platforms, electronic health record (EHR) systems, and insurer wellness programs.

The "third party" designation is broad. It spans HIPAA-covered entities (specialty clinics, hospitals), business associates (cloud hosting providers, analytics vendors), and entities not subject to HIPAA (employer wellness programs, direct-to-consumer health apps, device manufacturers themselves when acting outside a covered entity relationship). Each type of recipient carries a different legal designation and corresponding obligation. The data flow creates an expanding attack surface and a complex web of accountability. A patient might consent to share data with their endocrinologist, but the same patient may not be aware that the manufacturer’s software development kit (SDK) embedded in a third-party app is also collecting data for product improvement or advertising purposes.

HIPAA Privacy and Security Rules

The Health Insurance Portability and Accountability Act (HIPAA) remains the cornerstone of health data privacy in the United States for covered entities (health plans, healthcare clearinghouses, and healthcare providers who conduct standard electronic transactions) and their business associates. When a CGM device is prescribed and its data is managed within a healthcare system, HIPAA strictures apply. The patient’s glucose data is Protected Health Information (PHI). Before sharing this PHI with a third party, a covered entity must obtain a valid authorization from the patient unless an exception applies (treatment, payment, or healthcare operations without authorization).

A critical nuance arises when CGM data flows directly from a patient’s consumer-facing app to a third party without passing through a HIPAA-covered entity. In this case, the app developer and the third party are generally not HIPAA-bound unless they qualify as a business associate acting on behalf of a covered entity. The "App Exception" means that consumer health apps are largely regulated by other authorities, primarily state privacy laws and the Federal Trade Commission (FTC). This patchwork creates significant coverage gaps. For example, an employer-sponsored wellness program that asks an employee to share their CGM data in exchange for a premium discount is not necessarily a covered entity under HIPAA, leaving the employee with limited federal privacy protections.

The 21st Century Cures Act and Information Blocking

The 21st Century Cures Act and its implementing Final Rule from the Office of the National Coordinator for Health IT (ONC) introduced sweeping changes to health data access. The rule designates CGM data held by a healthcare provider as Electronic Health Information (EHI). Patients have a legal right to access this EHI without delay, and healthcare providers are prohibited from engaging in "information blocking" practices that unreasonably restrict the access, exchange, or use of EHI.

This regulatory push toward interoperability means that patients can direct their CGM data to be transmitted to any third-party application they choose, often via standardized APIs like HL7 FHIR. This empowers patients but also shifts the onus of privacy protection onto the patient at the point of data sharing. The provider must ensure the data is accessible, but they are not required to police what the third party does with it. This creates a strong imperative for patient education and clear consent mechanisms at the point where data exits the trusted clinical environment.

FDA Oversight of Medical Device Cybersecurity

The Food and Drug Administration (FDA) regulates CGM devices as class II medical devices. The agency’s pre-market and post-market cybersecurity guidance significantly impacts how CGM manufacturers secure their devices and associated data infrastructure. The FDA requires manufacturers to design security into their devices, including the interfaces that facilitate third-party data sharing. An insecure API or an unencrypted data stream from a sensor constitutes a device vulnerability that the manufacturer must address.

Recent FDA guidance emphasizes a total product lifecycle approach to cybersecurity. Manufacturers are expected to maintain a software bill of materials (SBOM), monitor for vulnerabilities, and issue timely patches. When a third-party integrator introduces a security flaw, the device manufacturer bears regulatory responsibility for the overall safety of the system, even if the flaw lies in the integrator’s code. This shared liability model makes contractual security requirements and rigorous vetting of third parties a regulatory necessity for CGM manufacturers.

FTC Enforcement and the Health Breach Notification Rule

The Federal Trade Commission (FTC) has become the primary privacy enforcer for digital health companies not covered by HIPAA. Under Section 5 of the FTC Act, the agency can pursue action against companies for unfair or deceptive acts or practices. A company that states in its privacy policy that it will not share health data but then sells that data to advertisers has committed a deceptive act. The FTC has also aggressively enforced the Health Breach Notification Rule against health apps. This rule requires vendors of personal health records (PHRs) and their third-party service providers to notify consumers, the FTC, and the media when unsecured identifiable health information is breached.

For CGM app developers, this rule is a critical compliance point. If a developer shares CGM data with a data analytics firm or an advertising network without explicit end-user authorization, that constitutes a breach triggering mandatory notifications. The FTC’s recent cases against EasyHealth and GoodRx illustrate the agency’s willingness to scrutinize health data sharing practices and impose significant civil penalties. Companies sharing CGM data must implement granular consent mechanisms and strictly limit data sharing to authorized purposes only to avoid regulatory exposure.

The European Union and International Regulatory Frameworks

GDPR: Special Category Data at High Risk

In the European Union, the General Data Protection Regulation (GDPR) classifies CGM data explicitly as "data concerning health" under Article 9(1). Processing of this special category data is generally prohibited unless an explicit legal basis exists. For most third-party sharing scenarios, the appropriate basis is explicit consent. Consent must be freely given, specific, informed, and unambiguous. The privacy impact of this standard is significant: a pre-checked box or a blanket acceptance of terms is insufficient. The data controller must obtain a clear affirmative action for each distinct sharing purpose.

Furthermore, because CGM data processing involves large-scale monitoring of health status, a Data Protection Impact Assessment (DPIA) is legally mandated under Article 35. The DPIA must systematically describe the processing, assess necessity and proportionality, and evaluate risks to data subjects. Mitigation measures—such as encryption, pseudonymization, and strict access controls—must be documented and implemented. The GDPR also grants data subjects a robust right to data portability (Article 20), allowing patients to request their raw CGM traces in a machine-readable format and transmit them directly to another controller, fostering competitive data sharing ecosystems.

Emerging International Standards

Jurisdictions around the world are enacting health-specific data protection laws. Brazil’s Lei Geral de Proteção de Dados (LGPD), Japan’s Act on Protection of Personal Information (APPI), and India’s Digital Personal Data Protection Act create local obligations that differ from HIPAA and GDPR. A U.S.-based CGM manufacturer sharing data with a research partner in another country must comply with local cross-border data transfer restrictions. Binding corporate rules, standard contractual clauses, and data localization requirements add layers of legal complexity to international data sharing arrangements.

The Ethical Dimensions of Data Sharing

Legal compliance alone is insufficient to build trust. The ethical dimensions of CGM data sharing require a higher standard, focusing on the underlying principles of autonomy, beneficence, non-maleficence, and justice.

True informed consent requires that patients understand the scope of data sharing, the identity of the recipients, the purpose of the processing, and the potential risks. This standard is often unmet in practice. End-user license agreements and privacy policies for CGM apps are dense, lengthy documents that few patients read. The phenomenon of "consent fatigue" leads to patients routinely clicking "agree" without comprehension. Ethical data sharing demands a shift toward granular, layered consent interfaces. A patient should be able to consent to share data for clinical care but explicitly decline sharing for product development or marketing. The system must also support dynamic consent, allowing patients to revisit and modify their choices over time.

Privacy, Stigma, and Discrimination

Even de-identified CGM data carries re-identification risk. Time-series glucose data is highly individualistic, a pattern akin to a biometric signature. A motivated actor—an insurer, an employer, a data broker—might cross-reference de-identified glucose traces with other datasets to re-identify specific patients. The consequences of re-identification can be severe. A person with poorly controlled diabetes might face higher insurance premiums, employment discrimination, or social stigma. The ethical duty is to assess and mitigate re-identification risk rigorously, limiting data retention and implementing robust access controls.

Justice, Equity, and Algorithmic Fairness

The benefits of CGM data aggregation are not shared equally. Datasets that train predictive algorithms are often drawn from populations with consistent access to care and technology. If a closed-loop insulin delivery system is trained primarily on data from affluent patients with Type 1 diabetes, its performance may degrade significantly for a low-income patient with Type 2 diabetes or for patients with gestational diabetes from diverse ethnic backgrounds. There is emerging evidence that sensor accuracy itself can vary by skin melanin levels, a biomechanical factor with profound implications for algorithmic fairness. Ethically, developers must ensure training data is representative and that models are validated across diverse demographics. Excluding underrepresented groups from the benefits of advanced diabetes algorithms perpetuates existing health disparities.

Data Ownership and the Right to Withdraw

A central ethical question remains: who owns the CGM data? The patient generates the data, the manufacturer provides the device, and the cloud platform stores the records. Legal ownership is often ambiguous. However, the ethical principle of autonomy supports the patient’s right to access, control, and delete their data. Third-party agreements must explicitly define data ownership. If a patient withdraws consent, the third party must delete the data, not merely anonymize it and continue using it for internal purposes. The path of the data after deletion must be traceable, and audits must confirm that copies are expunged from all backup systems.

Building a Trustworthy Governance Framework

Translating legal and ethical principles into practice requires a structured governance framework. The following elements are foundational for organizations that wish to responsibly share CGM data.

Conduct a Data Protection Impact Assessment

Before initiating any significant data sharing arrangement, perform a comprehensive DPIA (under GDPR) or Privacy Impact Assessment (under HIPAA). This assessment should identify the data elements being shared, map the data flow from source to recipient, evaluate the necessity and proportionality of the sharing, and document the risk mitigation measures. The DPIA is not a one-time exercise; it must be reviewed and updated when new third parties are added or when the scope of data sharing changes.

Implement Contractual Safeguards

Robust legal agreements are a non-negotiable safeguard. For HIPAA-covered data, a Business Associate Agreement (BAA) must be in place. For non-HIPAA data, a comprehensive Data Processing Agreement (DPA) should govern the relationship. These contracts must explicitly restrict the third party from using the data for any purpose other than the specified service. They should prohibit data sale, secondary use, and unauthorized disclosure. The contract should include standard security requirements, breach notification obligations, and audit rights.

Enforce Strict Technical Access Controls

Security architecture must align with the principle of data minimization. Third parties should receive only the data directly necessary for their function. Use tokenized access via OAuth 2.0 protocols to allow patients to grant and revoke application access without exposing their primary credentials. Encrypt data in transit (TLS 1.3) and at rest (AES-256). Maintain comprehensive audit logs that record every data access request. Implement a robust vulnerability management program and require third parties to do the same.

Empower Patients with Transparent Controls

Patients must be able to see exactly which third parties have access to their data and for what purpose. Provide clear, visual dashboards that list authorized applications and allow immediate revocation of access. When a patient revokes access, the system must trigger a deletion request to the third party and confirm compliance. Transparency builds trust; opacity invites suspicion and regulatory scrutiny.

Prepare for Breach Notification

Every organization sharing CGM data must assume a breach will eventually occur. A breach response plan should be in place, designating a response team, legal counsel, and a communications lead. Understand the specific notification timelines: HIPAA requires notification within 60 days, the GDPR demands notification to the supervisory authority within 72 hours of becoming aware of the breach, and the FTC Health Breach Notification Rule requires notification without unreasonable delay. Practice tabletop exercises to ensure the team can execute the plan under pressure.

Conclusion

The sharing of Continuous Glucose Monitoring data with third parties holds immense clinical and scientific promise. It connects patients with caregivers, enables population-level disease management, and powers the machine learning algorithms that will define the next generation of autonomous diabetes care. Yet, this promise is entirely contingent on trust—trust that the data will be protected, respected, and used solely for the benefit of the patient. Meeting this standard requires a dual commitment to rigorous legal compliance and proactive ethical stewardship. By understanding the complex regulatory environment of HIPAA, GDPR, FDA, and FTC mandates, and by embracing ethical principles of autonomy, equity, and transparency, the diabetes care community can build a data ecosystem that is both innovative and trustworthy. The path forward is not just about glucose responsiveness, but about rights-respecting, patient-centered data governance.